Building in efficacy: Developing solutions to combat drug resistant S. pneumoniae

Clinical Microbiology and Infection

Volumn 10, Issue SUPPL. 2, 2004, Pages 18-27

  Jacobs, M R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amoxicillin clavulanate; Drug development; Pharmacodynamics; Pharmacokinetics

Indexed keywords

14 HYDROXYCLARITHROMYCIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOPENICILLIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CETHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANATE POTASSIUM; CLINDAMYCIN; ERYTHROMYCIN; HMR 6004; KETOLIDE; LEVOFLOXACIN; MACROLIDE; OXAZOLIDINONE DERIVATIVE; PENICILLIN DERIVATIVE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROXITHROMYCIN; STREPTOGRAMIN DERIVATIVE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; DRUG DESIGN; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TARGETING; ERADICATION THERAPY; HAEMOPHILUS INFLUENZAE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PENICILLIN RESISTANCE; PREDICTION; PRIORITY JOURNAL; PROCESS OPTIMIZATION; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE; SUSTAINED DRUG RELEASE; SUSTAINED RELEASE FORMULATION; TABLET FORMULATION;

BACTERIA (MICROORGANISMS); HAEMOPHILUS; HAEMOPHILUS INFLUENZAE; MORAXELLA CATARRHALIS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 1242269055     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1470-9465.2004.00862.x     Document Type: Article

References (52)

1. Evans GM, Gaisford WF. Treatment of pneumonia with 2-(p-aminobenzenesulphonamido) pyridine. Lancet 1938; 2: 14-19.
2. Fine MJ, Auble TE, Yealy DM et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-250.
3. Song J-H. Bacterial eradication - rationale for antimicrobial assessment. Introduction: the goals of antimicrobial therapy. Int J Infect Dis 2003; 7 (Suppl. 1): S1-S4.
4. Marchant CD, Carlin SA, Johnson CE, Shurin PA. Measuring the comparative efficacy of antibacterial agents for acute otitis media: The 'Pollyanna phenomenon'. J Pediatr 1992; 120: 72-77.
5. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-246.
6. Kays MB, Wood KK, Miles DO. In vitro activity and pharmacodynamics of oral beta-lactam antimicrobials against Streptococcus pneumoniae from southeast Missouri. Pharmacotherapy 1999; 19: 1308-1314.
7. Lonks JR, Garau J, Gomez L et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-564.
8. Davidson R, Cavalcanti R, Brunton JL et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-750.
9. Dagan R, Johnson CE, McLinn S et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19: 95-104.
10. Dagan R. Can the choice of antibiotics for therapy of acute otitis media be logical? Eur J Clin Microbiol Infect Dis 1998; 17: 1-5.
11. Dagan R, Abramson O, Leibovitz E et al. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 1997; 176: 1253-1259.
12. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996; 15: 944-948.
13. Woodnutt G, Berry V. Two pharmacodynamic models for assessing the efficacy of amoxiciliin-clavulanate against experimental respiratory infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 29-34.
14. Ball P, Baquero F, Cars O et al. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002; 49: 31-40.
15. Craig WA. Re-evaluating current antibiotic therapy. Respir Med 2001; 95 (Suppl. A): S12-S19.
16. Craig WA, Kiem S, Andes DR. Free drug 24-hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin [abstract A-1264]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA: American Society of Microbiology, 2002; 14.
17. Craig WA, Andes D. Pattern of bactericidal activity with telithromycin against erythromycin-resistant Streptococcus pneumoniae (SP) in the murine thigh-infection model [abstract A-2098]. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL: American Society of Microbiology, 2002; 34.
18. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12.
19. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002; 19: 261-268.
20. den Hollander JG, Knudsen JD, Mouton JW et al. Comparison of pharmacodynamics of azithromycin and erythromycin in vitro and in vivo. Antimicrob Agents Chemother 1998; 42: 377-382.
21. Novelii A, Fallani S, Cassetta MI, Arrigucci S, Mazzei T. In vivo pharmacodynamic evaluation of clarithromycin in comparison to erythromycin. J Chemother 2002; 14: 584-590.
22. Hoffman HL, Klepser ME, Ernst EJ et al. Influence of macrolide susceptibliity of efficacies of clarithromycin and azithromycin against Streptococcus pneumoniae in a murine lung infection model. Antimicrob Agents Chemother 2003; 47: 739-746.
23. Dagan R, Leibovitz E, Fliss DM et al. Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000; 44: 43-50.
24. Howie VM, Ploussard JH. Efficacy of fixed combination antibiotics versus separate components in otitis media. Effectiveness of erythromycin estolate, triple sulfonomide, ampicillin, erythromycin estolate-triple sulfonomide, and placebo in 280 patients with acute otitis media under two and one-half years of age. Clin Pediatr (Phila) 1972; 11: 205-214.
25. Dagan R. Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles. Int J Infect Dis 2003; 7 (Suppl. 1): S21-S26.
26. Drusano GL, Craig WA. Relevance of pharmacokinetics and pharmacodynamics in the selection of antibiotics for respiratory tract infections. J Chemother 1997; 9: 38-44.
27. Sutcliffe J, Tait-Kamradt A, Wondrack L. Streptococcus pneumoniae and Streptococcus pyogenes resistant to macrolides but sensitive to clindamycin: a common resistance pattern mediated by an efflux system. Antimicrob Agents Chemother 1996; 40: 1817-1824.
28. Gay K, Baughman W, Miller Y et al. The emergence of Streptococcus pneumoniae resistant to macrolide antimicrobial agents: a 6-year population-based assessment. J Infect Dis 2000; 182: 1417-1424.
29. Marchandin H, Jean-Pierre H, Jumas-Bilak E et al. Distribution of macrolide resistance genes erm (B) and mef (A) among 160 penicillin-intermediate clinical isolates of Streptococcus pneumoniae isolated in southern France. Pathol Biol (Paris) 2001; 49: 522-527.
30. Peric M, Bozdogan B, Jacobs MR, Appelbaum PC. Effects of an efflux mechanism and ribosomal mutations on macrolide susceptibility of Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 2003; 47: 1017-1022.
31. Mitten MJ, Meulbroek J, Nukkala M et al. Efficacies of ABT-773, a new ketolide, against experimental bacterial infections. Antimicrob Agents Chemother 2001; 45: 2585-2593.
32. Garau J. Clinical failures: the tip of the iceberg? Respir Med 2001; 95 (Suppl. A): S5-S11.
33. Leggett JE, Fantin B, Ebert S et al. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281-292.
34. Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. J Am Med Assoc 1998; 279: 125-129.
35. Jacobs MR. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001; 7: 589-596.
36. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med 1999; 341: 233-239.
37. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 1999; 58: 29-36.
38. Craig WA. Antimicrobial resistance issues of the future. Diag Microbiol Infect Dis 1996; 25: 213-217.
39. Dagan R, Klugman K, Craig WA, Baquero F. Evidence to support the rationale that bacterial eradication in respiratory tract infection is an important aim of antimicrobial therapy. J Antimicrob Chemother 2001; 47: 129-140.
40. Ailani RK, Alimchandani A, Hidalgo J et al. Cephalosporin-resistant pneumococcal pneumonia: does it affect outcome? Respir Med 2002; 96: 805-811.
41. Urban A, Andes D, Craig WA. In-vivo activity of cefpodoxime against penicillin-resistant pneumococci [abstract 2229]. In: Abstracts of the 19th International Congress of Chemotherapy. Montreal, QE, Canada: International Society of Chemotherapy. Can J Infect Dis 1995; 6: 381C.
42. Andes D, Craig WA. In vivo activity of amoxicillin and amoxicillin/clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob Agents Chemother 1998; 42: 2375-2379.
43. Schito GC, Mannelli S, Pesce A, The Alexander Project Group. Trends in the activity of macrolide and β-lactam antibiotics and resistance development. J Chemother 1997; 9: 18-28.
44. Jacobs MR, Bajaksouzian S, Zilles A et al. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters. 1997 U.S. surveillance study. Antimicrob Agents Chemother 1999; 43: 1901-1908.
45. Kaye CM, Allen A, Perry S et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/clavulanate. Clin Ther 2001; 23: 578-584.
46. Jacobs MR. How can we predict bacterial eradication? Int J Infect Dis 2003; 7 (Suppl. 1): S13-S20.
47. Cooper CE, Slocombe B, White AR. Effect of low concentrations of clavulanic acid on the in-vitro activity of amoxycillin against beta-lactamase-producing Branhamella catarrhalis and Haemophilus influenzae. J Antimicrob Chemother 1990; 26: 371-380.
48. Finlay J, Miller L, Poupard JA. A review of the antimicrobial activity of clavulanate. J Antimicrobial Chemother 2003; 52: 18-23.
49. Petitpretz P, Chidiac C, Soriano F et al. The efficacy and safety of oral pharmacokinetically enhanced amoxycillin-clavulanate 2000/125 mg, twice daily, versus oral amoxycillin-clavulanate 1000/125 mg, three times daily, for the treatment of bacterial community-acquired pneumonia in adults. Int J Antimicrob Agents 2002; 20: 119-129.
50. Garau J, Twynholm M, Garcia-Mendez E, Siquier B, Rivero A, the 557 Clinical Study Group. Oral pharmacokinetically enhanced co-amoxiclav 2000/125 mg, twice daily, compared with co-amoxiclav 875/125 mg, three times daily, in the treatment of community-acquired pneumonia in European adults. J Antimicrob Chemother 2003; 52: 826-836.
51. File T, Lode H, Kurz H, Crann R. Comparative efficacy and safety of pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg vs amoxicillin/clavulanate 875/125 mg in community-acquired pneumonia (CAP) [abstract B11]. In: Abstracts from the 99th International Conference of the American Thoracic Society. Seattle, WA: American Thoracic Society, 2003; A370.
52. Anon J, Ferguson B, Wynne B, Kozak R. Pharmacokinetically enhanced amoxicillin/clavulanate 2000/125 mg twice daily in the the treatment of acute bacterial sinusitis (ABS) in adults [abstract 300]. In: Abstracts from the 41st Annual Meeting of the Infectious Diseases Society of America. San Diego, CA: Infectious Disease Society of America, 2003; 84.